BUZZ-Tevogen Bio jumps on expanded Microsoft AI collaboration

** Shares of drug developer Tevogen Bio TVGN.O rise ~48% to $2 premarket

** On Friday, TVGN said it is expanding its partnership with Microsoft MSFT.O to use AI to improve its immunotherapy treatments

** Co's proprietary tech, PredicTcell, will be developed on Microsoft's Azure cloud platform to identify precise T-cell targets - TVGN

** TVGN said it is also using MSFT's AI tools and Azure cloud platform to proactively investigate potential treatments for human papillomavirus - viral infection that can cause genital warts and certain types of cancer

** Last year, TVGN announced its partnership with Microsoft, and its shares surged to ~54%

** TVGN fell 90.7% in 2024